Impact of Insulin Receptor Substrate-1 rs956115 and CYP2C19 rs4244285 Genotypes on Clinical Outcome of Patients Undergoing Percutaneous Coronary Intervention.
Jiaxin Zong,Yingdan Tang,Tong Wang,Inam Ullah,Ke Xu,Jing Wang,Pengsheng Chen,Zengguang Chen,Tiantian Zhu,Jun Chen,Jimin Li,Fei Wang,Lu Yang,Yuansheng Fan,Lu Shi,Xiaoxuan Gong,John W. Eikelboom,Yang Zhao,Chunjian Li
DOI: https://doi.org/10.1161/jaha.121.025058
IF: 6.106
2022-08-06
Journal of the American Heart Association
Abstract:Background Insulin receptor substrate‐1 ( IRS‐1 ) rs956115 is associated with vascular risk in patients with coronary artery disease and concomitant diabetes. CYP2C19*2 (rs4244285) modulates clopidogrel response and predicts the outcome of coronary artery disease. This study was designed to explore the association between IRS‐1 , CYP2C19*2 genotypes, platelet reactivity, and 1‐year outcome in patients with coronary artery disease undergoing percutaneous coronary intervention. Methods and Results Genotyping was performed using an improved multiplex ligation detection reaction technique. Platelet aggregation was assessed by light transmission aggregometry. Major adverse cardiovascular events were defined as a composite of cardiovascular death, myocardial infarction, and ischemic stroke. A total of 2213 consecutive patients were screened and 1614 were recruited. At 1 month, patients with IRS‐1 CG genotype had significantly lower levels of ADP‐induced platelet aggregation compared with patients with CC homozygotes. Patients with IRS‐1 CG or GG genotype had a 2.09‐fold higher risk of major adverse cardiovascular events compared with those with CC homozygotes (95% CI, 1.04–4.19; P =0.0376). By comparison, patients with CYP2C19*2 GA or AA genotype had higher ADP‐induced platelet aggregation compared with patients with GG homozygotes. Although there was no significant difference in risk of major adverse cardiovascular events between patients with GA/AA and GG genotypes, patients with GA genotype had a 2.19‐fold higher risk than those with GG homozygotes (95% CI, 1.13–4.24; P =0.0200). No interaction between IRS‐1 and CYP2C19*2 genotypes was observed. Conclusions In patients following percutaneous coronary intervention, IRS‐1 GG/CG and CYP2C19*2 GA genotypes were associated with 2.09‐ and 2.19‐fold increased cardiovascular risk, respectively, at 1‐year follow‐up. The association between IRS‐1 genotypes and major adverse cardiovascular events appeared to be independent of known clinical predictors. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT01968499. Nonstandard Abbreviations and Acronyms AA arachidonic acid IRS‐1 insulin receptor substrate‐1 MACE major adverse cardiovascular events PL AA arachidonic acid induced platelet aggregation PL ADP ADP‐induced platelet aggregation Clinical Perspective What is New? In patients with recent percutaneous coronary intervention, insulin receptor substrate‐1 rs956115 G allele was associated with a 2.09‐fold higher cardiovascular risk at 1 year. The association between the insulin receptor substrate‐1 G allele and cardiovascular outcomes was independent of CYP2C19*2 genotypes and known clinical predictors. What are the Clinical Implications? Insulin receptor substrate‐1 genotyping provides further opportunity to improve risk stratification of individual patients undergoing percutaneous coronary intervention. The underlying mechanism linking insulin receptor substrate‐1 genotype and cardiovascular risk warrants further investigation. Insulin receptor substrate‐1 (IRS‐1), a ligand of insulin receptor tyrosine kinase, plays a central role in the insulin signal transduction system. 1 , 2 Dysregulation of IRS‐1 has been suggested as a common mechanism underlying insulin resistance that may lead to high platelet reactivity and low response to antiplatelet treatment in patients with type 2 diabetes. 3 , 4 CYP2C19 is one of the isoenzymes of the hepatic cytochrome P450 system, which plays a key role in the bioactivation of clopidogrel. 5 , 6 Patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI) who are carriers of CYP2C19 loss of function *2 (rs4244285) have lower levels of the active metabolite of clopidogrel than wild‐type homozygotes, which is -Abstract Truncated-
cardiac & cardiovascular systems